Q32 Bio Inc.

As of June 30, 2026, Q32 Bio Inc carries a market capitalization of 266.09M, placing it among publicly traded companies globally. Its enterprise value stands at 177.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Q32 Bio Inc's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Q32 Bio Inc has 23.74M shares outstanding.

As of June 30, 2026, Q32 Bio Inc trades at a trailing price-to-earnings ratio of 5.61. The price-to-sales ratio is 3.53, and the price-to-book ratio stands at 2.87.

As of June 30, 2026, Q32 Bio Inc trades at an EV/EBITDA multiple of 9.31 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 9.46 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 177.70M versus a market cap of 266.09M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Q32 Bio Inc maintains a current ratio of 20.30, meaning it holds 20.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.00, indicating elevated leverage, while an interest coverage ratio of 43.64 demonstrates strong ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on invested capital (ROIC) comes in at 36.48 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 37.13, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 58.28, useful for judging operating efficiency across full business cycles. The company generates approximately 1.65M in revenue per employee across its workforce of 28.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Q32 Bio Inc's stock has gained approximately 240.43% over the past 52 weeks. The 50-day moving average sits at 9.79, while the 200-day moving average is 7.99.

Over the twelve months ended June 30, 2026, Q32 Bio Inc generated 47.04M in revenue and converted that into 29.57M in net income, yielding earnings per share of 2.00. EBITDA reached 19.10M, while operating income came in at 18.79M.

As of June 30, 2026, Q32 Bio Inc holds 93.02M in cash and equivalents against 4.64M in total debt, resulting in a net debt position of -93.02M. Total book value stands at 92.70M, with working capital of 91.25M providing operational flexibility.

Q32 Bio Inc produced -17.36M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -17.36M - equivalent to -1.17 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of 39.94 and net profit margin of 62.87 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -10.45: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -21.14, meaning Q32 Bio Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Q32 Bio Inc's most recent stock split took place on March 26, 2024 with a 18:1 split ratio.

As of June 30, 2026, Q32 Bio Inc has an Altman Z-Score of 17.79, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.